Phase year global was Thanks our for Kristen. we Good Akebia morning program today. to for for of and considerable position advance a progress future. joining everyone XXXX and thanks for as the continue us vadadustat Akebia X
In If to vadadustat this full INNOXVATE worldwide for of Phase having made submitted partner on global program X the launch for over Japan, enrollment lead approved, strides vadadustat. Mitsubishi collaboration PROXTECT achieved first JNDA executing Tanabe in we year. expected specifically, our this a and is to great X,XXX patients. More vadadustat our
our balance team our capabilities a organization sheet commercial successfully strengthening added executed financing loan. non-dilutive a and term on we senior our team bolstered $XXX by million to and XXX-person strategy, members our We integrating nephrology-focused with
significant of As life continue these kidney a advancing our result shareholders. achievements, of with for to disease impacted and the value entered mission each person by XXXX opportunities to well-positioned long-term build our we better
up if XXXX more With many is exciting is shaping than milestones not the be developed what think equally on XXXX. horizon, already an vadadustat. forward path to We've significant I for exciting
Akebia So, on we're at in summarize throughout big coming and picture and months let focused me the the the year. what
of Our highest vadadustat. our execution priority remains program the X successful for Phase global
value we being the of our is developed largest investigational believe CKD, Our for driver. treatment which HIF-PHI due anemia to
that I'm begun. to quarter short that excited say in next readout first Phase for a countdown of program X Akebia our global to To the vadadustat. end to the our In plans has fact provide time, data just
patients CKD studies INNOXVATE expect in data report our on We topline from in anemia to to QX. dialysis due with
readouts us We It's approval. PROXTECT, we CKD non-dialysis studies all in introduction vadadustat into to consider to patients of to our expect of with energizing year. to this incredibly data to to the that commercial with follow regulatory are due and engine middle our of topline the at subject close data the how to anemia Akebia nephrology-focused from potential
CKD. make patients difference from lives due people in an anemia anemia the with X.X a suffer to incredible has due the U.S. to million CKD. Akebia opportunity of estimated in An to
the events. of body limitations and including disease cardiovascular managing are heart. most is notably and to the in by risk in kidneys organ affected the this the treating standard-of-care current There every disease Essentially this
current profile a with regulatory establish prescriber compared Our goal is vadadustat to the standard-of-care and as new with differentiated important oral a approval standard-of-care address patient upon ESAs. to safety needs
data commercial success. readouts tremendous program for believe clinical, expect clear and development a it's safety. regulatory importantly, clinical designed our for and amount of have efficacy and We we confidence in Very
believe injectable First, for readout is to safety MACE control enable designed vadadustat care alfa and the of the our from compare a cardiovascular using in adverse an order standard to are and further and of apart setting studies care. efficacy the clear and non-inferiority relevant to both standard active both current and and cardiovascular a need darbepoetin analysis the to assess and care. efficacy collection events this which put, understandable We believe will major that or ESA, us safety, straightforward of change INNOXVATE for across Simply competition. you of we PROXTECT ultimately data on standard
patients. a of informative data believe care about between class. HIF-PHIs highly both vadadustat these the and make dialysis and successful will current in non-dialysis consideration differentiating EU expect care. comparing And key in Going to a clear as with markets standard be in If little vadadustat. patients and physicians, drug differentiates studies, important first for its its payers these data the to We patient with outcomes into be the we class of U.S. deeper what the directly when they decisions
thoroughly European FDA was and with constructed global a extensive and regulators. Phase the have X which We dialogue after program, thoughtfully designed
our statistical of further plan increase agreed analysis success the our FDA FDA with the plan, margin with a EMA, a agreed the confidence statistical which straightforward place, non-inferiority have program. and on our in analysis we the and in to We and all key components of prospectively also defined of
all exciting important expected from year, very readouts we and Phase this line top a the for vadadustat. of X story program an in on period is believe this global our multiple data up levels sets Akebia program this incredibly So
the line from year. data INNOXVATE with ago, followed line middle set quarter, to we Consistent top by the of forth top this from PROXTECT over year a next timelines we expect data report
peer-reviewed communications the expect quiet in publication approaches, prepare from a investors venues period we plan journals. respect at would submit our as additional release. move can data for time to with presentation these into with analysts for that scientific the top you and so data and we'll As line to studies We and future analyze
not all. that's And
the vadadustat. an review. agreement think announced earlier, NDA exciting forward PRV As with developed I what for in with partner we potentially the access vadadustat our to Review Voucher mentioned Vifor to Pharma FDA expedite for I we've path dialysis Recently, Priority or is a an
While there's done, bringing would subject work this to as approval. of vadadustat as enhance path to more patients regulatory believe be possible we potential the quickly to meaningfully
of well facilitates a our believe in Otsuka positioned a we approval launch vadadustat dialysis we partner Pharma the up costs Vifor Finally, that agreement access U.S. very to strong the are coupled sharing and with our commercial organization. existing patients for launch and upon responsibilities, nephrology-focused to with XX% the with distribution
believe to our the strength and continue and Akebia. drive partnerships ways the in our advance with encouraged confidence partners our by vadadustat and have partnerships demonstrate allow both us effectively value cost pleased significant continue very to to that I'm investors. the to These of in potential for and I'm enthusiasm vadadustat we creatively
our you we're of When to plans, so design our the take accelerate experience, of the program, the all these our future. with PRV depth clinical see launch and potential efforts, excited our a about NDA of why can you
and stop numbers. there let the you Jason through take I'll
